Drug Insights

Maximize Your Synapse Use: Your Guide to Searching Olanzapine

21 February 2024
2 min read

The utilization of Zyprexa® or Olanzapine, an antipsychotic medication, is widely implemented in the treatment of schizophrenia, bipolar 1 disorder, and agitation concomitant with these conditions. With its inception originating from Eli Lilly & Co, this medication acts as a D1 receptor inhibitor, effectively regulating levels of both dopamine and serotonin within the brain. Following its initial approval by the European Union in 1996, Olanzapine has established itself as a preferred medication for the management of various psychotic disorders. Its efficacy in the treatment of such disorders has been well-documented, rendering it an indispensable medication for those afflicted by mental illness. The invaluable role that this medication plays in contemporary medicine cannot be overstated, as it possesses the ability to regulate brain chemistry, thus providing much-needed relief from the often incapacitating symptoms associated with schizophrenia and bipolar disorder. Click on the image below to begin the exploration journey of Olanzapine through the Synapse database!

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Alisertib Phase II Trial for Small Cell Lung Cancer Begins: ALISCA-Lung1
Latest Hotspot
3 min read
Alisertib Phase II Trial for Small Cell Lung Cancer Begins: ALISCA-Lung1
20 February 2024
Puma Biotechnology has launched a Phase II study for Alisertib, targeting Small Cell Lung Cancer, named ALISCA-Lung1.
Read →
Zelenirstat: A Quick Look at Its R&D Progress and Clinical Results from the 2024 ASCO_GI
Zelenirstat: A Quick Look at Its R&D Progress and Clinical Results from the 2024 ASCO_GI
20 February 2024
Zelenirstat, an effective oral NMT inhibitor, showed promising results in treating advanced relapsed/refractory cancer at 2024's ASCO_GI.
Read →
Galderma's Nemolizumab for Prurigo Nodularis and Eczema Approved for Submission in US and EU
Latest Hotspot
3 min read
Galderma's Nemolizumab for Prurigo Nodularis and Eczema Approved for Submission in US and EU
20 February 2024
Galderma declares submission approval of Nemolizumab for treating Prurigo Nodularis and Eczema in America and Europe.
Read →
Master Tretinoin Search on Synapse
Drug Insights
2 min read
Master Tretinoin Search on Synapse
20 February 2024
Vesanoid, also known as Tretinoin, is a vitamin A derivative that has been given the green light for treating acne vulgaris and specific forms of promyelocytic leukemia.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.